Debio 0123, a highly selective WEE1 inhibitor, in combination with carboplatin (C) and etoposide (E), in patients with recurrent small cell lung cancer (SCLC): determination of recommended dose (RD) from a phase 1 escalation

Poster presented at ASCO 2025

Valentina Gambardella¹, Alejandro Navarro², Prantesh Jain³, Jose Maria Lopez-Picazo⁴, Gonzalo Fernandez⁵, Jon Zugazagoitia⁶, Maria de Miguel⁷, Sirish Gadgeel⁸, Sajjad Bhatti⁹, Pedro Rocha², Anna Vilalta Lacarra⁴, Esteban Rodrigo Imedio¹⁰, Sandrine Micallef¹⁰, Jonathan Wessen¹⁰, Vito Dozio¹⁰, Rikke Frederiksen Franzen¹⁰, Anne Bellon¹⁰, Luis Paz-Ares⁶

¹ Hospital Clinico Universitario de Valencia, Valencia, Spain
² Hospital Universitario Vall d’Hebron, Barcelona, Spain
³ Roswell Park Cancer Institute, Buffalo, Cancer Institute, Buffalo, NY, USA
⁴ Clinica Universidad de Navarra, Pamplona, Spain
⁵ Clinica Universidad de Navarra, Madrid, Spain
⁶ Hospital Universitario 12 de Octubre,Madrid, Spain
⁷ Hospital Universitario HM Sanchinarro, Madrid, Spain
⁸ Henry Ford Health System, Detroit, MI, USA
⁹ University of Arkansas for Medical Sciences, Little Rock, AR, USA
¹⁰ Debiopharm International SA, Chemin Messidor 5-7, CP 435, 1001 Lausanne, Switzerland